Literature DB >> 24319171

Helicobacter pylori and mucosa-associated lymphoid tissue: what's new.

Sung-Hsin Kuo1, Ann-Lii Cheng.   

Abstract

Low-grade mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach, gastric MALT lymphoma, is associated with Helicobacter pylori infection. The eradication of H pylori using antibiotics is successful in 60% to 80% of affected patients. In contrast to the previous paradigm, we and other investigators have shown that a certain proportion of patients with H pylori-positive early-stage diffuse large B-cell lymphoma (DLBCL) of the stomach with histological evidence of MALT lymphoma, including high-grade transformed gastric MALT lymphoma and gastric DLBCL(MALT), achieved long-term complete pathological remission (pCR) after first-line H pylori eradication therapy, indicating that the loss of H pylori dependence and high-grade transformation are separate events in the progression of gastric lymphoma. In addition, patients with H pylori-positive gastric DLBCL without histological evidence of MALT (gastric pure DLBCL) may also respond to H pylori eradication therapy. A long-term follow-up study showed that patients who achieved pCR remained lymphoma free. Gastric MALT lymphoma is indirectly influenced by H pylori infection through T-cell stimulation, and recent studies have shown that H pylori-triggering chemokines and their receptors, H pylori-associated epigenetic changes, H pylori-regulated miRNA expression, and tumor infiltration by CD4+CD25+ regulatory T cells contribute to lymphomagenesis of gastric MALT lymphoma. Recent studies have also demonstrated that the translocation of CagA into B lymphocytes inhibits apoptosis through p53 accumulation, BAD phosphorylation, and the up-regulation of Bcl-2 and Bcl-XL expression. In gastric MALT lymphoma, CagA may stimulate lymphomagenesis directly, through the regulation of signal transduction, and intracellular CagA is associated with H pylori dependence. These findings represent a substantial paradigm shift compared with the classical theory of H pylori-reactive T cells contributing indirectly to the development of MALT lymphoma. In conclusion, a wide range of H pylori-related gastric lymphomas have been identified. The use of antibiotics as the sole first-line therapy for early-stage gastric pure DLBCL requires validation in a prospective study. The clinical and biological significance of the CagA oncoprotein in the lymphomagenesis of gastric MALT lymphoma warrants further study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24319171     DOI: 10.1182/asheducation-2013.1.109

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  17 in total

Review 1.  Helicobacter pylori eradication in gastric diffuse large B cell lymphoma.

Authors:  Semra Paydas
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

2.  A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue.

Authors:  Hui-Jen Tsai; John Jen Tai; Li-Tzong Chen; Ming-Shiang Wu; Kun-Huei Yeh; Chung-Wu Lin; Tsang-En Wang; Hsiu-Po Wang; Fang-Jung Yu; Jyh-Ming Liou; Chin-Fu Hsiao; Tsu-Yao Cheng; Hong-Jen Yeh; Chung-Wang Ko; Ming-Jen Chen; Gin-Ho Lo; Ping-I Hsu; Cheng-Shyong Chang; Wei-Shou Hwang; Shih-Sung Chuang; Hsiao-Wei Lee; Chia-Tung Shun; Chang-Fang Chiu; Wen-Ming Wang; Ching-Yun Hsieh; Tsang-Wu Liu; Jaw-Town Lin; Sung-Hsin Kuo; Ann-Lii Cheng
Journal:  Haematologica       Date:  2019-11-14       Impact factor: 9.941

3.  A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma.

Authors:  Carol S Portlock; Paul A Hamlin; John F Gerecitano; Ariela Noy; Maria Lia Palomba; Janelle Walkley; Stacie Corcoran; Jocelyn Migliacci; Heiko Schoder; Genovefa Papanicolaou; Arnold J Markowitz
Journal:  Tumor Microenviron Ther       Date:  2015-02-18

Review 4.  Clinical aspects of malt lymphomas.

Authors:  Christina Kalpadakis; Gerassimos A Pangalis; Theodoros P Vassilakopoulos; Stavroula Kyriakaki; Xanthi Yiakoumis; Sotirios Sachanas; Maria Moschogiannis; Pantelis Tsirkinidis; Penelope Korkolopoulou; Helen A Papadaki; Maria K Angelopoulou
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

5.  A Rare Case of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Transforming into Diffuse Large B-Cell Lymphoma.

Authors:  Fasil Tiruneh; Ahmad Awan; Raka Amin; Samina Afreen; Abdullahi Musa; Wayne Davis
Journal:  Cureus       Date:  2017-06-20

Review 6.  Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.

Authors:  Nathan M Denlinger; Narendranath Epperla; Basem M William
Journal:  Cancer Manag Res       Date:  2018-03-27       Impact factor: 3.989

7.  First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Sung-Hsin Kuo; Kun-Huei Yeh; Ming-Shiang Wu; Chung-Wu Lin; Ming-Feng Wei; Jyh-Ming Liou; Hsiu-Po Wang; Li-Tzong Chen; Ann-Lii Cheng
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

8.  Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity.

Authors:  S-H Kuo; K-H Yeh; L-T Chen; C-W Lin; P-N Hsu; C Hsu; M-S Wu; Y-S Tzeng; H-J Tsai; H-P Wang; A-L Cheng
Journal:  Blood Cancer J       Date:  2014-06-20       Impact factor: 11.037

9.  CagA Phosphorylation in Helicobacter pylori-Infected B Cells Is Mediated by the Nonreceptor Tyrosine Kinases of the Src and Abl Families.

Authors:  Linda M Krisch; Gernot Posselt; Peter Hammerl; Silja Wessler
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

10.  Increased colon cancer risk after severe Salmonella infection.

Authors:  Lapo Mughini-Gras; Michael Schaapveld; Jolanda Kramers; Sofie Mooij; E Andra Neefjes-Borst; Wilfrid van Pelt; Jacques Neefjes
Journal:  PLoS One       Date:  2018-01-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.